SELLAS Life Sciences signaled a catalyst-heavy 2026 in acute myeloid leukemia. The company is approaching the final overall survival event in its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in AML patients in complete remission after second-line salvage therapy, with 72 of the prespecified 80 events recorded. It also opened an expansion cohort evaluating SLS009 (tambiciclib), a CDK9 inhibitor, in newly diagnosed first-line AML, building on positive mid-stage data in relapsed/refractory disease. A new European collaboration through the IMPACT-AML STREAM network will study SLS009 with azacitidine and venetoclax in approximately 40 newly diagnosed patients starting in the second quarter. The balance sheet has been strengthened to support these readouts, with $71.8 million in cash at year-end 2025 and an additional $42.6 million raised via warrant exercises in the first quarter of 2026.
The strategic question is whether SELLAS can translate two mechanistically distinct bets into a coherent AML franchise. GPS aims to consolidate remission in an ultra-high-risk niche where relapse is the norm and treatment choices are limited. SLS009 targets a different problem: overcoming or delaying venetoclax resistance by suppressing MCL-1 via CDK9 inhibition, then moving that benefit earlier in the treatment continuum. If the Phase 3 survival signal for GPS is compelling and the SLS009 program sustains its activity and tolerability alongside venetoclax-based backbones, SELLAS could shape two decision points in AML care rather than a single line of therapy.
This matters now because AML standards are in flux. Frontline azacitidine plus venetoclax has reset expectations, but resistance and poor outcomes in molecularly adverse subsets persist. In SELLAS’s Phase 2 study of SLS009 plus azacitidine/venetoclax in relapsed/refractory AML with myelodysplasia-related changes after prior venetoclax-based therapy, the overall response rate reached 46% across 35 evaluable patients, with responses observed in ASXL1- and TP53-mutated disease. Median overall survival in the least pretreated cohort reached 8.9 months, versus historical expectations measured in weeks, and the triplet regimen was reported as tolerable without dose-limiting toxicities. For clinicians, this raises the prospect of rationally designed triplets for genomically high-risk patients; for payers, it underscores the need for biomarker-informed positioning and robust real-world data to validate durability and resource use in routine practice.
The REGAL readout is equally consequential for the immunotherapy narrative in myeloid malignancies. AML has been resistant to immune approaches that transformed solid tumors, and a clear survival benefit in post-salvage remission could open a new consolidation paradigm. The event-driven design, focused on overall survival rather than surrogate endpoints, could ease payer and guideline adoption if positive, while also clarifying the role for GPS as a maintenance-like strategy in a setting underserved by transplant or intensive chemotherapy.
Beyond clinical science, this update reflects broader sector dynamics. The move to expand studies through a pan-European trial network fits the industry’s shift toward distributed enrollment models that can accelerate accrual in narrow populations. The reliance on warrant exercises to add more than $100 million across late 2025 and early 2026 highlights the ongoing reconfiguration of biotech financing, allowing companies to bridge to pivotal data without traditional follow-ons in a volatile capital market.
The next six to nine months will determine whether SELLAS can convert momentum into market leverage. The timing of the 80th survival event in REGAL, the magnitude and safety of the topline benefit, and the consistency of SLS009 activity in earlier-line combinations will shape regulatory options, pricing power, and partnering interest. The strategic hinge is clear: can GPS redefine consolidation in high-risk AML and can SLS009 credibly extend the azacitidine/venetoclax era, or will the field’s rapid evolution outpace these advances?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
